Immunochemotherapy - A Missed Opportunity for Metastasized Malignant Melanoma? Reporting a Therapeutic Success with Checkpoint Inhibitor Rechallenge after Cytotoxic Immuno-Priming in a Heavily Pretreated Patient

Treatment of metastasized malignant melanoma still has very limited therapeutic options. After exhaustion of immuno-checkpoint inhibition (ICI) and potentially targeted therapy, no promising alternatives are currently available. We report on an 83-year-old patient suffering from disseminated metasta...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiderlen, Til R., Delmastro, Nicola, Jobst, Friedemann, de Wit, Maike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459574/
https://www.ncbi.nlm.nih.gov/pubmed/36158860
http://dx.doi.org/10.1159/000525153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459574/
https://www.ncbi.nlm.nih.gov/pubmed/36158860
http://dx.doi.org/10.1159/000525153

Ejemplares similares